A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...

Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

Safety and efficacy of FGFR inhibitors in urothelial carcinoma: A systematic review and meta-analysis. Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients ...

A research team from the National Center for Nanoscience and Technology of the Chinese Academy of Sciences, in collaboration with Chongqing Medical University, has developed three types of ...

Overall survival from the open label phase 2 trial of palbociclib in patients with advanced well differentiated/dedifferentiated liposarcoma. An update on the results ...